Search Results: Endometrial Cancer (31 results)
IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/266 /helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.
Virtual Exercise Classes for Adult Cancer Survivors (SURGE)
https://www.facingourrisk.org/research-clinical-trials/study/445 /virtual-exercise-classes-for-adult-cancer-survivors-surge
Quality of Life
Exercise study for people diagnosed within the past 5 years
This study compares live, online group exercise classes with recorded exercise videos to see how they affect physical activity, physical fitness, quality of life, and loneliness among cancer survivors.
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.
REKINDLE: Your Ability to Cope With a Life-Changing Medical Diagnosis
https://www.facingourrisk.org/research-clinical-trials/study/423 /rekindle-your-ability-to-cope-with-a-life-changing-medical-diagnosis
Quality of Life
Study for those experiencing mental health struggles due to a diagnosis of cancer or other medical illness
A diagnosis of cancer or other serious medical condition changes everything — including your mental health. Those experiencing negative mental health changes after receiving a diagnosis may be dealing with what is known as Adjustment Disorder.
Psilocybin Therapy in Advanced Cancer
https://www.facingourrisk.org/research-clinical-trials/study/436 /psilocybin-therapy-in-advanced-cancer
Quality of Life
Study for people with advanced cancer
This study is looking at whether psilocybin-assisted psychotherapy may help people with advanced cancer who are experiencing significant anxiety, depression, or emotional and spiritual distress related to their cancer.
Please Help us Learn More About Immunotherapy Side Effects That People With Cancer Experience
https://www.facingourrisk.org/research-clinical-trials/study/421 /a-5-minute-patient-and-caregiver-survey-to-share-experiences-with-immunotherapy-and-any-short-term-or-long-term-side-effects
Surveys, Registries, Interviews
Survey on immunotherapy to share experiences, including side effects and whether they were resolved or not
This Patient and Caregiver survey was created by volunteers from two non-profit groups to learn more about immunotherapy side effects. No personal information is collected. Goals include sharing results with doctors, care teams, and patient groups; gathering information about better ways to handle immune-related side effects; and working with researchers to find and test better ways to treat immune-related side effects.
Study of Dostarlimab Immunotherapy in People with Mismatch Repair-Deficient Endometrial Cancer Who Wish to Preserve Fertility
https://www.facingourrisk.org/research-clinical-trials/study/434 /a-phase-ii-study-of-dostarlimab-immunotherapy-in-people-with-mismatch-repair-deficient-endometrial-who-wish-to-preserve-fertility
Treatment
Treatment study for people with MSI-H or dMMR early-stage endometrial cancer
In this study, researchers are testing the safety and effectiveness of the immunotherapy dostarlimab (Jemperli) as a non-surgery alternative treatment option for patients with early-stage dMMR or MSI-H endometrial cancer and a strong desire for fertility preservation. Doctors will evaluate patients' response to dostarlimab; patients whose tumors respond completely can be followed with close surveillance and no surgery.
Testing the Drug CX-5461 for Treating Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/431 /testing-the-drug-cx-5461-for-treating-metastatic-solid-tumors
Treatment
Phase 1 study for treatment of advanced solid tumors
This early-phase study is looking at the safety, side effects, and best dose of the medication pidnarulex for treating advanced or metastatic cancers. Pidnarulex blocks a certain protein called Pol 1 that cells need to repair DNA damage.
Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)
https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8
Treatment
Treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Researchers are studying whether the targeted therapy ETX-19477 is a safe and effective treatment option for people with metastatic or advanced solid tumors. ETX-19477 is a type of drug known as a PARG inhibitor. It works by interfering with cancer cells' ability to repair damage to their DNA. Researchers hope this may slow tumor growth or cause cancer cells to die.The goal of this study is to find the safest and most effective dose of ETX-19477 for treating metastatic or advanced cancers. The study is currently enrolling people with a BRCA1 or BRCA2 mutation.
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle
Treatment
Post-treatment study to monitor for recurrence
This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor DNA (ctDNA), tiny pieces of cancer DNA that may be present in the bloodstream. Researchers want to learn how well this test can:
- Detect cancer recurrence early
- Predict outcomes after treatment
- Support future use of blood‑based monitoring instead of—or in addition to—imaging tests
SCREEN-CUP: Menstrual Cup Screening for Endometrial Cancer in Lynch Syndrome
https://www.facingourrisk.org/research-clinical-trials/study/398 /screen-cup-menstrual-cup-screening-for-endometrial-cancer-in-lynch-syndrome
Prevention
Screening study for endometrial cancer
This study is looking at whether a menstrual cup can be used as a simple, non-invasive way to collect menstrual blood for detection of endometrial (uterine) cancer earlier—especially in people with Lynch syndrome or others at high risk.
An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)
https://www.facingourrisk.org/research-clinical-trials/study/385 /an-early-detection-and-prevention-study-for-people-with-an-increased-risk-of-cancer-inadvance
Prevention
Study for people at risk of cancer, including previvors, survivors and family members
This study collects health information and DNA samples such as blood or saliva from participants to help researchers better understand cancer risk and early detection.
Comparing an Experimental Drug Puxi-Sam to Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)
https://www.facingourrisk.org/research-clinical-trials/study/370 /comparing-an-experimental-drug-puxi-sam-with-standard-chemotherapy-for-metastatic-endometrial-cancer-bluestarendometrial01
Treatment
Phase 3 treatment study for metastatic endometrial cancer
This study is testing whether a new targeted drug called puxitatug samrotecan (Puxi-Sam) works better than standard chemotherapy for treating advanced or metastatic endometrial cancer whose cancer has grown or returned after prior treatment with platinum chemotherapy and immunotherapy.
Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab
https://www.facingourrisk.org/research-clinical-trials/study/408 /treating-advanced-solid-tumors-with-the-rason-inhibitor-daraxonrasib-combined-with-a-targeted-immunotherapy-ivonescimab
Treatment
Treatment study for solid tumors with a RAS mutation
This study is testing whether combining a new type of targeted drug called RAS(ON) inhibitors with an immunotherapy drug called ivonescimab is safe and may help slow or shrink cancer in people with advanced or metastatic solid tumors that have a biomarker called a RAS mutation.
Treating Advanced Endometrial Cancer with Targeted Therapies (ComboMATCH)
https://www.facingourrisk.org/research-clinical-trials/study/375 /treating-advanced-endometrial-or-ovarian-cancer-with-targeted-therapies-combomatch
Phase 2 treatment study for recurrent endometrial cancer
This clinical trial is testing whether two targeted cancer drugs taken together work better than one drug alone for treating advanced endometrial cancer that has come back or did not respond to prior treatment. To be eligible, the cancer must test positive for a biomarker known as a RAS pathway mutation.
The EASE Study: Helping People with Advanced Cancer Cope with Fear of Cancer Progression
https://www.facingourrisk.org/research-clinical-trials/study/413 /the-ease-study-helping-people-with-advanced-cancer-cope-with-fear-of-cancer-progression
Quality of Life
Quality of life study for people with advanced cancer experiencing anxiety
This study is testing a new approach to help people with different types of advanced cancer cope with fear about their cancer getting worse. The study will compare whether a short series of guided writing sessions delivered by telehealth works better than usual supportive care.
Study of a Blood Test to Look for Signs of Cancer in Higher-Risk People (CHARM2)
https://www.facingourrisk.org/research-clinical-trials/study/393 /study-of-a-blood-test-to-look-for-signs-of-cancer-in-higher-risk-people-charm2
Prevention
Blood test to find cancers earlier in high-risk people
This study is looking at how well an experimental blood test works for finding cancer earlier in people who have a higher-than-average risk of cancer because of an inherited mutation. Note: This study is only open in Canada.
Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab
https://www.facingourrisk.org/research-clinical-trials/study/362 /testing-an-immunotherapy-drug-nivolumab-with-or-without-the-immunotherapy-drug-ipilimumab-for-recurrent-dmmr-endometrial-cancer
Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker
This clinical trial is studying two different immunotherapy approaches for people with endometrial cancer that has come back after treatment (recurrent). It focuses on tumors that have a biomarker called mismatch repair deficiency, (dMMR or MMR-D) or microsite instability high (MSI-High). These biomarkers are often found in cancers that respond to immunotherapy.
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
This clinical trial is studying whether the combination of two targeted therapies, abemaciclib (Verzenio) and a new targeted therapy ZEN003694 (also known as ZEN-3694) can be given together safely and what dose should be used in future studies.
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Treatment
Treatment study for people with advanced or metastatic solid tumors
The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.
The DETECT Study: Detecting Endometrial Cancer in Tampons
https://www.facingourrisk.org/research-clinical-trials/study/306 /the-detect-study-detecting-endometrial-cancer-in-tampons
Prevention
Early detection of endometrial cancer in women undergoing hysterectomy surgery at the University of Alabama
This study will test whether endometrial samples from tampons can be used for early detection of endometrial cancer and is open to women over 45 years of age who are undergoing hysterectomy surgery (surgery to remove the uterus)
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/310 /effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer
Treatment
People with stage I endometrial cancer who are having a hysterectomy
This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.
Registry to Discover New Treatments and Developmental Processes of Colorectal and Endometrial Cancer in Patients with Hereditary Cancer
https://www.facingourrisk.org/research-clinical-trials/study/301 /registry-to-discover-new-treatments-and-developmental-processes-of-colorectal-and-endometrial-cancer-in-patients-with-hereditary-cancer
Surveys, Registries, Interviews
Registry for people who screen for colorectal endometrial cancer
This research registry will collect and save data, cancer samples and family health history information to discover new ways cancer develops. It will look to find new genes that could be used for treatments and preventing cancer for people with hereditary cancer.
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311 /study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas.
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/245 /a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Treatment
Phase 2 treatment study for recurrent endometrial cancer
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Self -Perception and Intimacy After the Cancer Experience (SPICE)
https://www.facingourrisk.org/research-clinical-trials/study/247 /self-perception-and-intimacy-after-the-cancer-experience-spice
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
SPICE is an online survey that asks questions about your sexuality, sexual health knowledge, interpersonal relationships, and body image. Participants will be asked questions about their body image, impact of cancer, relationships, and how they feel about their sexuality.
Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/333 /study-of-the-drug-tng260-and-an-immunotherapy-in-advanced-solid-tumors-with-a-stk11-mutation
Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations
The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.
Cancer Experience Registry
https://www.facingourrisk.org/research-clinical-trials/study/248 /cancer-experience-registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
https://www.facingourrisk.org/research-clinical-trials/study/251 /study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:
- have a tumor marker known as microsatellite stable (MSS), OR
- have been treated with and no longer respond to treatment with immunotherapy drugs known as immune checkpoint inhibitors.
RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer
https://www.facingourrisk.org/research-clinical-trials/study/192 /restore-a-virtual-study-comparing-2-digital-apps-to-improve-mental-and-physical-well-being-of-patients-with-stage-i-3-cancer
People with stage 1-3 cancer
Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.
Additional Results on Clinicaltrials.gov Endometrial Cancer
269 results
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT ID: NCT07383506 (https://clinicaltrials.gov/study/NCT07383506)
Screening and Staging of Benign vs Malignant Pelvic Abnormalities
NCT ID: NCT07407959 (https://clinicaltrials.gov/study/NCT07407959)
Improving Care for Rural Patients With Solid Tumors
NCT ID: NCT04916990 (https://clinicaltrials.gov/study/NCT04916990)
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
NCT ID: NCT05559879 (https://clinicaltrials.gov/study/NCT05559879)
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT ID: NCT06276491 (https://clinicaltrials.gov/study/NCT06276491)
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT ID: NCT04977453 (https://clinicaltrials.gov/study/NCT04977453)
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
NCT ID: NCT06315257 (https://clinicaltrials.gov/study/NCT06315257)
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT06586957 (https://clinicaltrials.gov/study/NCT06586957)
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
NCT ID: NCT07306559 (https://clinicaltrials.gov/study/NCT07306559)
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
NCT ID: NCT04016389 (https://clinicaltrials.gov/study/NCT04016389)
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT07909031 (https://clinicaltrials.gov/study/NCT07909031)
A Community Based Intervention to Improve Cervical Cancer Screening Among Women in the Hispanic and East African Immigrant Community
NCT ID: NCT07890402 (https://clinicaltrials.gov/study/NCT07890402)
Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer
NCT ID: NCT07631572 (https://clinicaltrials.gov/study/NCT07631572)
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT ID: NCT04839614 (https://clinicaltrials.gov/study/NCT04839614)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT ID: NCT06465069 (https://clinicaltrials.gov/study/NCT06465069)
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT ID: NCT07109726 (https://clinicaltrials.gov/study/NCT07109726)
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT ID: NCT07524322 (https://clinicaltrials.gov/study/NCT07524322)
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
NCT ID: NCT05941507 (https://clinicaltrials.gov/study/NCT05941507)
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
NCT ID: NCT05721976 (https://clinicaltrials.gov/study/NCT05721976)
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
NCT ID: NCT07594015 (https://clinicaltrials.gov/study/NCT07594015)
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT ID: NCT07182149 (https://clinicaltrials.gov/study/NCT07182149)
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT ID: NCT06999187 (https://clinicaltrials.gov/study/NCT06999187)
Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-care
NCT ID: NCT06850402 (https://clinicaltrials.gov/study/NCT06850402)
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
NCT ID: NCT06814496 (https://clinicaltrials.gov/study/NCT06814496)
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)
Emergency Department-based Cervical Cancer Screening Through Self-sampling
NCT ID: NCT07345897 (https://clinicaltrials.gov/study/NCT07345897)
NYSCF Scientific Discovery Biobank
NCT ID: NCT06203106 (https://clinicaltrials.gov/study/NCT06203106)
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT ID: NCT07444814 (https://clinicaltrials.gov/study/NCT07444814)
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT ID: NCT04469764 (https://clinicaltrials.gov/study/NCT04469764)
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT ID: NCT03422198 (https://clinicaltrials.gov/study/NCT03422198)
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT ID: NCT03564340 (https://clinicaltrials.gov/study/NCT03564340)
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
NCT ID: NCT06365905 (https://clinicaltrials.gov/study/NCT06365905)
Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer
NCT ID: NCT05761561 (https://clinicaltrials.gov/study/NCT05761561)
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT ID: NCT06022029 (https://clinicaltrials.gov/study/NCT06022029)
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT ID: NCT07470853 (https://clinicaltrials.gov/study/NCT07470853)
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
NCT ID: NCT05975593 (https://clinicaltrials.gov/study/NCT05975593)
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT ID: NCT06535607 (https://clinicaltrials.gov/study/NCT06535607)
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT ID: NCT06330064 (https://clinicaltrials.gov/study/NCT06330064)
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
NCT ID: NCT07281599 (https://clinicaltrials.gov/study/NCT07281599)
Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer
NCT ID: NCT06529809 (https://clinicaltrials.gov/study/NCT06529809)
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT ID: NCT07262619 (https://clinicaltrials.gov/study/NCT07262619)
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT ID: NCT05990426 (https://clinicaltrials.gov/study/NCT05990426)
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT ID: NCT03968406 (https://clinicaltrials.gov/study/NCT03968406)
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT ID: NCT05366881 (https://clinicaltrials.gov/study/NCT05366881)
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
NCT ID: NCT07278986 (https://clinicaltrials.gov/study/NCT07278986)
Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
NCT ID: NCT07382583 (https://clinicaltrials.gov/study/NCT07382583)
Mindfulness in Endometrial and Cervical Cancer
NCT ID: NCT04512144 (https://clinicaltrials.gov/study/NCT04512144)
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
NCT ID: NCT04865887 (https://clinicaltrials.gov/study/NCT04865887)
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
NCT ID: NCT05475171 (https://clinicaltrials.gov/study/NCT05475171)
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT ID: NCT05103683 (https://clinicaltrials.gov/study/NCT05103683)
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
NCT ID: NCT04774419 (https://clinicaltrials.gov/study/NCT04774419)
Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT ID: NCT04570553 (https://clinicaltrials.gov/study/NCT04570553)
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT ID: NCT05283330 (https://clinicaltrials.gov/study/NCT05283330)
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
NCT ID: NCT07281430 (https://clinicaltrials.gov/study/NCT07281430)
Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome
NCT ID: NCT07106359 (https://clinicaltrials.gov/study/NCT07106359)
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT ID: NCT06047379 (https://clinicaltrials.gov/study/NCT06047379)
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://clinicaltrials.gov/study/NCT04997096)
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT ID: NCT06481592 (https://clinicaltrials.gov/study/NCT06481592)
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT ID: NCT05377996 (https://clinicaltrials.gov/study/NCT05377996)
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
NCT ID: NCT05512208 (https://clinicaltrials.gov/study/NCT05512208)
A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://clinicaltrials.gov/study/NCT05107674)
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
NCT ID: NCT07327489 (https://clinicaltrials.gov/study/NCT07327489)
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT ID: NCT05856981 (https://clinicaltrials.gov/study/NCT05856981)
PopSci CHW4CervixHealth
NCT ID: NCT07336134 (https://clinicaltrials.gov/study/NCT07336134)
Sentinel Node Biopsy in Endometrial Cancer
NCT ID: NCT04073706 (https://clinicaltrials.gov/study/NCT04073706)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://clinicaltrials.gov/study/NCT05112601)
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT ID: NCT06340568 (https://clinicaltrials.gov/study/NCT06340568)
HPV Vaccine, Imiquimod, and Metformin Combination Trial
NCT ID: NCT06686043 (https://clinicaltrials.gov/study/NCT06686043)
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
NCT ID: NCT06855706 (https://clinicaltrials.gov/study/NCT06855706)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://clinicaltrials.gov/study/NCT04300556)
Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer
NCT ID: NCT07867002 (https://clinicaltrials.gov/study/NCT07867002)
Unidos Contra el VPH
NCT ID: NCT06825689 (https://clinicaltrials.gov/study/NCT06825689)
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT ID: NCT03452774 (https://clinicaltrials.gov/study/NCT03452774)
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT ID: NCT07020221 (https://clinicaltrials.gov/study/NCT07020221)
Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions.
NCT ID: NCT07351110 (https://clinicaltrials.gov/study/NCT07351110)
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
NCT ID: NCT03675893 (https://clinicaltrials.gov/study/NCT03675893)
Hypofractionated Radiochemotherapy
NCT ID: NCT06331468 (https://clinicaltrials.gov/study/NCT06331468)
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT ID: NCT05797168 (https://clinicaltrials.gov/study/NCT05797168)
Investigations of Reproductive Cancers in Women
NCT ID: NCT06527157 (https://clinicaltrials.gov/study/NCT06527157)
A Study of PHST001 in Advanced Solid Tumors
NCT ID: NCT06840886 (https://clinicaltrials.gov/study/NCT06840886)
Sample Collection for Ongoing Research and Product Evaluation Study
NCT ID: NCT07318051 (https://clinicaltrials.gov/study/NCT07318051)
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT ID: NCT04389632 (https://clinicaltrials.gov/study/NCT04389632)
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT ID: NCT06952504 (https://clinicaltrials.gov/study/NCT06952504)
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
NCT ID: NCT07664735 (https://clinicaltrials.gov/study/NCT07664735)
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT ID: NCT07216703 (https://clinicaltrials.gov/study/NCT07216703)
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
NCT ID: NCT06266338 (https://clinicaltrials.gov/study/NCT06266338)
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
NCT ID: NCT07643012 (https://clinicaltrials.gov/study/NCT07643012)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT ID: NCT07198074 (https://clinicaltrials.gov/study/NCT07198074)
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT ID: NCT06128551 (https://clinicaltrials.gov/study/NCT06128551)
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
NCT ID: NCT07814248 (https://clinicaltrials.gov/study/NCT07814248)
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT ID: NCT06952660 (https://clinicaltrials.gov/study/NCT06952660)
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT ID: NCT05902988 (https://clinicaltrials.gov/study/NCT05902988)
The Ohio State University (OSU) SCREEN Community Program
NCT ID: NCT06666192 (https://clinicaltrials.gov/study/NCT06666192)
Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women
NCT ID: NCT07011836 (https://clinicaltrials.gov/study/NCT07011836)
Fasting InTervention for Endometrial Cancer
NCT ID: NCT07622901 (https://clinicaltrials.gov/study/NCT07622901)
Rice Technologies for Cervical Cancer Screening and Diagnosis
NCT ID: NCT05372484 (https://clinicaltrials.gov/study/NCT05372484)
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT ID: NCT07022483 (https://clinicaltrials.gov/study/NCT07022483)
A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
NCT ID: NCT07318415 (https://clinicaltrials.gov/study/NCT07318415)
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT ID: NCT00005095 (https://clinicaltrials.gov/study/NCT00005095)
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
NCT ID: NCT05639972 (https://clinicaltrials.gov/study/NCT05639972)
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT ID: NCT06369155 (https://clinicaltrials.gov/study/NCT06369155)
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
NCT ID: NCT05049538 (https://clinicaltrials.gov/study/NCT05049538)
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
NCT ID: NCT05952141 (https://clinicaltrials.gov/study/NCT05952141)
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT ID: NCT07166094 (https://clinicaltrials.gov/study/NCT07166094)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT ID: NCT07419841 (https://clinicaltrials.gov/study/NCT07419841)
Reducing Urban Cervical Cancer Disparities
NCT ID: NCT06416150 (https://clinicaltrials.gov/study/NCT06416150)
Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy
NCT ID: NCT07662824 (https://clinicaltrials.gov/study/NCT07662824)
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
NCT ID: NCT07542704 (https://clinicaltrials.gov/study/NCT07542704)
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT ID: NCT05646316 (https://clinicaltrials.gov/study/NCT05646316)
Image-Guided Gynecologic Brachytherapy
NCT ID: NCT02993900 (https://clinicaltrials.gov/study/NCT02993900)
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
NCT ID: NCT07318324 (https://clinicaltrials.gov/study/NCT07318324)
Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
NCT ID: NCT07292818 (https://clinicaltrials.gov/study/NCT07292818)
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT ID: NCT05592626 (https://clinicaltrials.gov/study/NCT05592626)
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
NCT ID: NCT06677190 (https://clinicaltrials.gov/study/NCT06677190)
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT ID: NCT04567771 (https://clinicaltrials.gov/study/NCT04567771)
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT04895709 (https://clinicaltrials.gov/study/NCT04895709)
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT ID: NCT07186842 (https://clinicaltrials.gov/study/NCT07186842)
MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
NCT ID: NCT06677112 (https://clinicaltrials.gov/study/NCT06677112)
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT ID: NCT06974110 (https://clinicaltrials.gov/study/NCT06974110)
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT07229313 (https://clinicaltrials.gov/study/NCT07229313)
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT ID: NCT06253494 (https://clinicaltrials.gov/study/NCT06253494)
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT ID: NCT05548296 (https://clinicaltrials.gov/study/NCT05548296)
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT ID: NCT07216105 (https://clinicaltrials.gov/study/NCT07216105)
Comprehensive Outcomes for After Cancer Health
NCT ID: NCT05349227 (https://clinicaltrials.gov/study/NCT05349227)
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
NCT ID: NCT07741968 (https://clinicaltrials.gov/study/NCT07741968)
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
NCT ID: NCT04329494 (https://clinicaltrials.gov/study/NCT04329494)
Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening
NCT ID: NCT07453459 (https://clinicaltrials.gov/study/NCT07453459)
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT ID: NCT05579366 (https://clinicaltrials.gov/study/NCT05579366)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT ID: NCT06239194 (https://clinicaltrials.gov/study/NCT06239194)
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05797831 (https://clinicaltrials.gov/study/NCT05797831)
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT ID: NCT06964009 (https://clinicaltrials.gov/study/NCT06964009)
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT ID: NCT07189871 (https://clinicaltrials.gov/study/NCT07189871)
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT ID: NCT05867251 (https://clinicaltrials.gov/study/NCT05867251)
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
NCT ID: NCT05838521 (https://clinicaltrials.gov/study/NCT05838521)
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT ID: NCT07807345 (https://clinicaltrials.gov/study/NCT07807345)
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT ID: NCT04291612 (https://clinicaltrials.gov/study/NCT04291612)
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT ID: NCT04486352 (https://clinicaltrials.gov/study/NCT04486352)
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT ID: NCT07213609 (https://clinicaltrials.gov/study/NCT07213609)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
NCT ID: NCT07749586 (https://clinicaltrials.gov/study/NCT07749586)
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT ID: NCT06242470 (https://clinicaltrials.gov/study/NCT06242470)
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)
Cervical Cancer Detection Using Optical Spectroscopy
NCT ID: NCT00900575 (https://clinicaltrials.gov/study/NCT00900575)
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
NCT ID: NCT06925724 (https://clinicaltrials.gov/study/NCT06925724)
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT ID: NCT07503808 (https://clinicaltrials.gov/study/NCT07503808)
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
NCT ID: NCT06689956 (https://clinicaltrials.gov/study/NCT06689956)
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://clinicaltrials.gov/study/NCT05603910)
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT ID: NCT06906341 (https://clinicaltrials.gov/study/NCT06906341)
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT ID: NCT05503797 (https://clinicaltrials.gov/study/NCT05503797)
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT ID: NCT06730347 (https://clinicaltrials.gov/study/NCT06730347)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT ID: NCT07285044 (https://clinicaltrials.gov/study/NCT07285044)
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT ID: NCT06293898 (https://clinicaltrials.gov/study/NCT06293898)
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
NCT ID: NCT07286331 (https://clinicaltrials.gov/study/NCT07286331)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://clinicaltrials.gov/study/NCT06270706)
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
NCT ID: NCT07121543 (https://clinicaltrials.gov/study/NCT07121543)
Avera Cancer Sequencing and Analytics Protocol (ASAP)
NCT ID: NCT05142033 (https://clinicaltrials.gov/study/NCT05142033)
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
NCT ID: NCT07407647 (https://clinicaltrials.gov/study/NCT07407647)
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT ID: NCT04657068 (https://clinicaltrials.gov/study/NCT04657068)
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
NCT ID: NCT04743674 (https://clinicaltrials.gov/study/NCT04743674)
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT ID: NCT05051722 (https://clinicaltrials.gov/study/NCT05051722)
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://clinicaltrials.gov/study/NCT05489211)
Integrated Cancer Repository for Cancer Research
NCT ID: NCT02012699 (https://clinicaltrials.gov/study/NCT02012699)
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
NCT ID: NCT07197554 (https://clinicaltrials.gov/study/NCT07197554)
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT ID: NCT04683653 (https://clinicaltrials.gov/study/NCT04683653)
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT ID: NCT07044336 (https://clinicaltrials.gov/study/NCT07044336)
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT ID: NCT07114601 (https://clinicaltrials.gov/study/NCT07114601)
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT ID: NCT04038619 (https://clinicaltrials.gov/study/NCT04038619)
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
NCT ID: NCT07755436 (https://clinicaltrials.gov/study/NCT07755436)
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
NCT ID: NCT07415681 (https://clinicaltrials.gov/study/NCT07415681)
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT ID: NCT05819892 (https://clinicaltrials.gov/study/NCT05819892)
[18F]FES PET/.CT in Uterine Cancer
NCT ID: NCT05916196 (https://clinicaltrials.gov/study/NCT05916196)
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT ID: NCT04586959 (https://clinicaltrials.gov/study/NCT04586959)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05919264 (https://clinicaltrials.gov/study/NCT05919264)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://clinicaltrials.gov/study/NCT01174121)
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
NCT ID: NCT07214584 (https://clinicaltrials.gov/study/NCT07214584)
Distance-Based Exercise to Preserve Function and Prevent Disability
NCT ID: NCT07059884 (https://clinicaltrials.gov/study/NCT07059884)
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
NCT ID: NCT04093388 (https://clinicaltrials.gov/study/NCT04093388)
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT ID: NCT03832361 (https://clinicaltrials.gov/study/NCT03832361)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT ID: NCT06760819 (https://clinicaltrials.gov/study/NCT06760819)
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
NCT ID: NCT04165772 (https://clinicaltrials.gov/study/NCT04165772)
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
NCT ID: NCT06042543 (https://clinicaltrials.gov/study/NCT06042543)
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT ID: NCT07227168 (https://clinicaltrials.gov/study/NCT07227168)
Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies
NCT ID: NCT07447895 (https://clinicaltrials.gov/study/NCT07447895)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://clinicaltrials.gov/study/NCT04851119)
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
NCT ID: NCT05979610 (https://clinicaltrials.gov/study/NCT05979610)
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
NCT ID: NCT07223424 (https://clinicaltrials.gov/study/NCT07223424)
Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).
NCT ID: NCT07022470 (https://clinicaltrials.gov/study/NCT07022470)
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NCT ID: NCT07270666 (https://clinicaltrials.gov/study/NCT07270666)
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
NCT ID: NCT05758688 (https://clinicaltrials.gov/study/NCT05758688)
Navigation Intervention for Adolescent and Young Adult Cancer Survivors
NCT ID: NCT07406087 (https://clinicaltrials.gov/study/NCT07406087)
Uterine Preservation Via Lifestyle Transformation
NCT ID: NCT05903131 (https://clinicaltrials.gov/study/NCT05903131)
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT ID: NCT06096688 (https://clinicaltrials.gov/study/NCT06096688)
Vaginal Cuff Brachytherapy Fractionation Study
NCT ID: NCT03785288 (https://clinicaltrials.gov/study/NCT03785288)
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
NCT ID: NCT04723095 (https://clinicaltrials.gov/study/NCT04723095)
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT ID: NCT06463028 (https://clinicaltrials.gov/study/NCT06463028)
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT06040970 (https://clinicaltrials.gov/study/NCT06040970)
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
NCT ID: NCT06492070 (https://clinicaltrials.gov/study/NCT06492070)
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
NCT ID: NCT06349642 (https://clinicaltrials.gov/study/NCT06349642)
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT ID: NCT06515613 (https://clinicaltrials.gov/study/NCT06515613)
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT ID: NCT05997017 (https://clinicaltrials.gov/study/NCT05997017)
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
NCT ID: NCT07064018 (https://clinicaltrials.gov/study/NCT07064018)
A Study of VET3-TGI in Patients With Solid Tumors
NCT ID: NCT06444815 (https://clinicaltrials.gov/study/NCT06444815)
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT ID: NCT04104776 (https://clinicaltrials.gov/study/NCT04104776)
Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers
NCT ID: NCT05606133 (https://clinicaltrials.gov/study/NCT05606133)
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT ID: NCT06395519 (https://clinicaltrials.gov/study/NCT06395519)
Detecting HPV DNA in Anal and Cervical Cancers
NCT ID: NCT04857528 (https://clinicaltrials.gov/study/NCT04857528)
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT ID: NCT06695845 (https://clinicaltrials.gov/study/NCT06695845)
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
NCT ID: NCT07107334 (https://clinicaltrials.gov/study/NCT07107334)
A Study of DM002 in Patients With Advanced Solid Tumors
NCT ID: NCT06751329 (https://clinicaltrials.gov/study/NCT06751329)
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT ID: NCT06157151 (https://clinicaltrials.gov/study/NCT06157151)
Building Connections
NCT ID: NCT07091032 (https://clinicaltrials.gov/study/NCT07091032)
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial
NCT ID: NCT07436793 (https://clinicaltrials.gov/study/NCT07436793)
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT ID: NCT05542407 (https://clinicaltrials.gov/study/NCT05542407)
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT05950464 (https://clinicaltrials.gov/study/NCT05950464)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
NCT ID: NCT06319963 (https://clinicaltrials.gov/study/NCT06319963)
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT ID: NCT06708429 (https://clinicaltrials.gov/study/NCT06708429)
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT ID: NCT05669430 (https://clinicaltrials.gov/study/NCT05669430)
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT ID: NCT04831580 (https://clinicaltrials.gov/study/NCT04831580)
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
NCT ID: NCT06409052 (https://clinicaltrials.gov/study/NCT06409052)
Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking
NCT ID: NCT05977621 (https://clinicaltrials.gov/study/NCT05977621)
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT ID: NCT06989112 (https://clinicaltrials.gov/study/NCT06989112)
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT ID: NCT06993844 (https://clinicaltrials.gov/study/NCT06993844)
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
NCT ID: NCT03538665 (https://clinicaltrials.gov/study/NCT03538665)
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT ID: NCT06774963 (https://clinicaltrials.gov/study/NCT06774963)
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
NCT ID: NCT04590326 (https://clinicaltrials.gov/study/NCT04590326)
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT06172478 (https://clinicaltrials.gov/study/NCT06172478)
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT ID: NCT05686226 (https://clinicaltrials.gov/study/NCT05686226)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://clinicaltrials.gov/study/NCT05483491)
Improving Rural Endometrial Cancer Care
NCT ID: NCT07927244 (https://clinicaltrials.gov/study/NCT07927244)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
NCT ID: NCT07458347 (https://clinicaltrials.gov/study/NCT07458347)
Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy
NCT ID: NCT07075731 (https://clinicaltrials.gov/study/NCT07075731)
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT ID: NCT04196257 (https://clinicaltrials.gov/study/NCT04196257)
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://clinicaltrials.gov/study/NCT05208762)
Multimedia Aid for Genetic Testing in Gynecologic Oncology
NCT ID: NCT07084168 (https://clinicaltrials.gov/study/NCT07084168)
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)
NCT ID: NCT07770100 (https://clinicaltrials.gov/study/NCT07770100)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT ID: NCT06943521 (https://clinicaltrials.gov/study/NCT06943521)
Molecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic Surgery
NCT ID: NCT07044505 (https://clinicaltrials.gov/study/NCT07044505)
Study of EV for Recurrent Endometrial Carcinoma
NCT ID: NCT07139977 (https://clinicaltrials.gov/study/NCT07139977)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://clinicaltrials.gov/study/NCT05564377)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
NCT ID: NCT07467772 (https://clinicaltrials.gov/study/NCT07467772)
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT ID: NCT05691010 (https://clinicaltrials.gov/study/NCT05691010)
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
NCT ID: NCT07227077 (https://clinicaltrials.gov/study/NCT07227077)
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
NCT ID: NCT07220239 (https://clinicaltrials.gov/study/NCT07220239)
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT ID: NCT05969860 (https://clinicaltrials.gov/study/NCT05969860)
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
NCT ID: NCT06128304 (https://clinicaltrials.gov/study/NCT06128304)
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT ID: NCT07578649 (https://clinicaltrials.gov/study/NCT07578649)
Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
NCT ID: NCT07527143 (https://clinicaltrials.gov/study/NCT07527143)
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT ID: NCT05983432 (https://clinicaltrials.gov/study/NCT05983432)
A Multicenter Cancer Biospecimen Collection Study
NCT ID: NCT04510129 (https://clinicaltrials.gov/study/NCT04510129)
The Better, Harder, Faster, Stronger Study
NCT ID: NCT07220512 (https://clinicaltrials.gov/study/NCT07220512)
Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice, RCT
NCT ID: NCT06872346 (https://clinicaltrials.gov/study/NCT06872346)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://clinicaltrials.gov/study/NCT05092373)
IDOV-Immune for Advanced Solid Tumors
NCT ID: NCT06910657 (https://clinicaltrials.gov/study/NCT06910657)
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
NCT ID: NCT06538337 (https://clinicaltrials.gov/study/NCT06538337)
ALPINE: Maintenance Letrozole/Abemaciclib
NCT ID: NCT06366347 (https://clinicaltrials.gov/study/NCT06366347)
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
NCT ID: NCT06795009 (https://clinicaltrials.gov/study/NCT06795009)
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
NCT ID: NCT07224464 (https://clinicaltrials.gov/study/NCT07224464)
Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
NCT ID: NCT07062016 (https://clinicaltrials.gov/study/NCT07062016)
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
NCT ID: NCT07209449 (https://clinicaltrials.gov/study/NCT07209449)
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05914116 (https://clinicaltrials.gov/study/NCT05914116)
DESTINY-PANTUMOUR04
NCT ID: NCT07124000 (https://clinicaltrials.gov/study/NCT07124000)
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT ID: NCT05640999 (https://clinicaltrials.gov/study/NCT05640999)
Tirzepatide in Obesity-Driven Endometrial Cancer
NCT ID: NCT07065552 (https://clinicaltrials.gov/study/NCT07065552)
Pilot Study for Speculum Free Cervical Cancer Screening
NCT ID: NCT04107181 (https://clinicaltrials.gov/study/NCT04107181)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://clinicaltrials.gov/study/NCT05039801)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.